New medicinal glass packaging:
Type I glass molded bottles: mainly used for packaging plasma, albumin, globulin and other products, specifications in 20ml-100ml.
Type I glass control bottles: mainly used for packaging lyophilized biological agents, powder injections, vaccines, genetic engineering drugs and other products, specifications in 3ml-12ml, mainly 2ml-8ml, large specifications also have 32ml.
Clip-on bottle: foreign countries have partially replaced the injection Ampoule for packaging high-end large-capacity liquid dosage form drugs, domestic mainly for insulin injection packaging.
Pre-filled syringes: mainly used for packaging vaccines, interferon and other biological drugs, is a one-time drug-containing injections.
Brief introduction of two major glass packaging companies in Europe and America: There is no pure medical glass packaging company in the world
US OI: the world's largest glass packaging manufacturer, OI glass packaging involves food, beverages, cosmetics and pharmaceuticals, glass packaging revenue accounted for 89% of its business income, the other 11% is a plastic packaging, 2005 OI sales scale is 7079 Billion U.S. dollars, including glass packaging sales of 630 billion U.S. dollars.
Saint Gobain, France: The Saint Gobain business involves five areas. The packaging revenue only accounts for 11% of the company's business revenue. In 2005, the sales volume was 479.9 billion US dollars, and the glass packaging scale was even smaller. One of the company's five major businesses is Flat glass business.
Chinese medicine packaging has gone through three phases:
In the 50-60s: Brown bottles, straw cartons, and straight neck ampoule were the main packaging, and medicines were bulky and practical.
In the 60-80s, it was greatly influenced by the Cultural Revolution. From the end of the 1960s to the end of the 1970s, there was no registered trademark on pharmaceutical packaging. It was the painful period for pharmaceutical packaging in China and the development of pharmaceutical packaging was completely stagnant.
From the 1980s to the present: In the early 1980s, the registered trademark of drugs was restored, and the pharmaceutical packaging industry began to develop healthily. Composite materials such as aluminum-plastic, paper-plastic, and laser anti-counterfeit packaging materials were gradually popularized.
On April 29, 2004, China promulgated the "Measures for the Administration of Materials and Containers for Pharmaceutical Packaging (Provisional)", which classifies pharmaceutical packaging materials into three categories: I, II, and III:
Category I refers to materials and containers for pharmaceutical packaging that are directly in contact with drugs and used directly;
II refers to direct contact with drugs, but easy to clean, in the actual use of the process, after cleaning and can be disinfected and sterilized drug packaging materials, containers;
Category III refers to materials and containers for pharmaceutical packaging that may directly affect the quality of drugs other than Class I and II.
At present, the main pharmaceutical packaging materials mainly include the following major categories:
Rubber packing material: It mainly appears in the form of stoppers and gaskets for containers, which are divided into natural rubber and butyl rubber. Due to the poor sealability of natural rubber, it is necessary to seal the wax to supplement it, and the chemical properties are unstable. The government has been eliminated from the list. The butyl rubber has excellent sealing performance and replaces the natural rubber plug as an injection package.
Metal packaging materials: aluminum caps, pastes and aerosols used for powder injection packaging, and pharmaceutical aluminum foils for aluminum-plastic blister packaging. Aluminum-plastic composite covers have been accepted by more and more markets due to their easy opening and safe use. The aluminum-aluminum packaging developed in recent years is a new type of packaging material, which has a strong barrier property and can prolong the shelf life of drugs, and is particularly suitable for drugs with poor chemical stability.
Glass packaging material: It is widely used in the fields of injections, powder injections, biological medicines, blood products, lyophilizers, and oral liquids. Glass has good chemical stability, is not affected by the atmosphere, is not decomposed by solid or liquid substances of different chemical compositions, and the chemical properties and radiation resistance properties of the glass can be adjusted by changing the chemical composition of the glass, and the glass is transparent and beautiful. , low price, recyclable, etc., will not cause environmental problems.
Composite packaging materials: mainly including oral solid plastic bottles, liquid plastic bottles, etc., mostly made of high-density polyethylene or polypropylene, polyester materials.
2. China's largest pharmaceutical glass packaging company
Established in 1970, Shandong Pharmaceutical Glass Co., Ltd. started from antibiotic glass packaging, adopted low price to seize market share and continuously carried out technological innovation market strategy. The market share of molded antibiotic bottle reached 79%. It is the largest pharmaceutical glass packaging production enterprise in China.
At present, the company can produce six series of more than 400 kinds of products including molded antibiotic bottles, ampoules, control bottles, infusion bottles, glass tubes, and brown bottles, as well as butyl rubber stoppers, aluminum plastic caps, and plastic bottles, and have been successfully developed. Neutral borosilicate I glass has become the first domestic pharmaceutical glass packaging company capable of producing Class I glass in the world.
The company's total share capital is 222 million yuan, with unlimited sales of 155 million outstanding shares. The controlling shareholder of Wuyuan County Public Assets Management Committee holds 24.84% of the company's shares, unlimited-sale tradable shareholders hold 69.51% of the company's shares, and other limited-sale tradable shareholders hold 5.63% of the company's shares .
The company's main raw material soda ash accounts for about 10% of production costs, and the main energy-consuming coal accounts for about 18% of production costs. In 2004, the price of soda ash increased and the price of coal rose. Production costs rose by more than 30 million, and the government was originally scheduled for 2004. On December 31st, the butyl rubber stopper completely replaced the natural rubber stopper and the antibiotic stopper was delayed until June 30, 2005. The infusion stopper was postponed until December 31, 2005, which greatly affected the effectiveness of the raised funds. Even so, the company Still, through the technological innovation, the costs have risen and the profits have been steadily increasing.
3. Leading by size and cost, membrane resistance bottle is cash flow business
The antibiotic powder injection accounted for the absolute sales volume in the injection market in China. The company cultivated finely in the field of pharmaceutical glass packaging and formed a strong technical advantage. The market share of the membrane-resistant bottle reached 79%, and the production efficiency was higher than 70% of its counterparts. The interest rate is 10 points higher than that of competitors. Relying on technological innovation, the company's market competition strategy is to continuously reduce the price of common specification model anti-bottles, and to introduce high-gross-rate new products to replace old ones and gradually force competitors out of the market. It is expected that urban consumption in the antibiotic market will shrink in China, and rural consumption will increase steadily. The company is the main manufacturer of antibiotic molded bottles. The future size of membrane-resistant bottles is stable. The transfer to the Baotou industry may effectively reduce costs, and membrane resistance bottles become stable cash for the company. Streaming business.
Giants in antibiotic powder industry win customers with size and cost
The penicillin powder industry, which accounts for 70% of the antibiotic powder market share, shows high industrial concentration. 50-60% of production capacity is concentrated in four major manufacturers: Harbin Pharmaceuticals, Shijiazhuang Pharmaceuticals, North China Pharmaceuticals and Lukang Pharmaceuticals, including North China Pharmaceuticals. The annual production of penicillin powder is about 1.2 billion, which is mainly used in the packaging of controlled bottles. The remaining three companies use about 4 billion mold-resistant bottles each year. The company's mold-resistant bottles reach 8.7 billion, and it has the ability to cover downstream customers. We think the scale will become upstream. The bottleneck of competition in the packaging industry.
In recent years, the sales scale of the company’s top five sales customers has been stable at 1.8-1.9 billion yuan. Harbin Pharmaceuticals, Northeast Pharmaceuticals, Stone Drugs, Qilu, Shanghai Pioneer, and Shanghai New Asia, the heavyweight producers of antibiotic powder, are basically the company’s Drug companies are exploring the entry into the molded bottle industry. However, Shandong Pharmaceutical Glass Mould-resistance bottle prices are lower than drug companies entering the Mould-resistance bottle industry. They also make pharmaceutical companies continue to give up sales of more than 500 million yuan. Mold resistant bottle industry.
In addition, because pharmaceutical glass bottles account for a small proportion of drug value (1-10%), the first choice of glass bottles for downstream companies is to consider the stability of the quality of glass bottles in the process of continuous batch filling of large quantities of drugs and their suitability for filling equipment. The company has established a long-term and stable cooperative relationship with nearly 800 customers. The quality of the molded bottles produced has been fully adapted to the requirements of the downstream manufacturers on the mechanical strength and specifications of the bottles, which makes the company's customers have a good Continuity and stability.
Gross profit margin is 10 points higher than that of competitors, and profit is earned by technological superiority
In recent years, the company has continuously invested funds for technological transformation, and has independently developed domestic leading technologies such as lightweight thin-wall mold resistant bottle production technology, high white material mold anti-bottle production technology, servo parallel shear feeding technology, electric servo material feeding technology, and small-mouth pressure blowing technology. , For the transformation of purchased production equipment, not only the product quality has been improved, but also the production efficiency has been greatly improved. The production efficiency of one mold anti-bottle production line has been higher than 70% of the counterparts in 2003 and 2004, which makes the company model resistant to bottle hair. The interest rate is far higher than the average gross margin of the industry by more than ten points (the company's model bottle resistance rate was 41% in 2005, and the average gross margin of the industry was about 30%). The sales price of some products was close to the counterparty cost price, and the company completely relied on technological advantages to win. Take profits.
In 2004, when the cost increased by more than 30 million, the company improved its production efficiency through technological optimization. The company digested the cost of 25 million yuan, and the model-resistant bottle gross margin remained high, reflecting the company’s strong internal management, technical capabilities, and competitiveness.
Adjust product structure and stabilize the leading position in the industry
At present, the company's mold resistance bottle specifications from the 5ml-100ml nearly 300 species, while the peer company can only produce a maximum of 10 specifications. Through the continuous introduction of high-gross new product replacements, lowering the price of competitors' existing model-resistant bottles, cracking down on competitors and gradually forcing competitors out of the market, the company’s market strategy has achieved absolute results, and the industry’s leading position has been steadily consolidated.
In response to the trend of modularization and anti-bottles, the company took advantage of 30 years of accumulated experience in the glass packaging industry to continuously research and develop new-type die-resistant bottles. It is the first lightweight, high-grade, and large-format one in the industry, leading the industry in consumer trends, and Saint Gobain in France fights for Pfizer's high-end customers.
Membrane resistance bottle transfer to Baotou industry will effectively reduce costs and become a cash flow business
As China's unique prescription drug clinical marketing model, urban hospital sales of oral antibiotics swollen, antibiotic powder is mainly on the amount of "virtual praise", sales of water is not great, but with the rational rationality of medication, the future of China's urban hospital antibiotics The consumption of injections has shrunk, and rural areas have become the main force for the increase in the consumption of antibiotics. The company is the main manufacturer of membrane-resistant bottles, and the scale of membrane-resistant bottles is stable in the future.
Membrane resistance bottles are being transferred to the Baotou industry. Due to the availability of local coal and soda ash and tax concessions of 15%, Baotou’s subsidiary Kangyu’s strategic positioning is a company’s Class III glass mold resistant bottle production base. The local coal price is only RMB 200/ton. (Company headquarters 506 yuan / ton), electricity price 0.40 yuan / degree (Corporate headquarters 0.57 yuan / degree), we expect membrane resistance to the entire bottle after the transfer, the long-term gross margin may rise to 45-46%, membrane resistance bottle future contributions to the company The net profit will stabilize at 80 million to 110 million yuan, becoming the company's cash flow business.
4. Take the road of technological innovation, and gradually approach the multinational giants
Before 2003, all technologies of the company centered on the glass industry, and had strong technological advantages in glass packaging. In the pharmaceutical industry, it was only a registered barrier for pharmaceutical packaging controlled by the government. After the intervention in the production of butyl rubber plugs in 2003, the company used pharmaceuticals. Glass packaging began to be fully integrated with drugs. Medicinal glass packaging is not a simple glass bottle, but a medicinal glass that can guarantee the safety of injected drugs. Drug packaging must also be compatible with drugs while packaging drugs. Sex will not react with drugs, causing greater drug safety problems.
Continuous technological innovation in the field of pharmaceutical packaging, product upgrading in 2007
The company's membrane resistant bottles continued to undergo technological transformation and the technical potential was basically brought into play. In 2003, the "bottle + lid" strategy was involved in butyl rubber stoppers. The company's glass packaging began to merge with the pharmaceutical industry. In 2004, the company developed I-type glass for two years. Difficulties, breakthrough in technology in 2006; success in 2007 relying on type I glass, the company will undergo a qualitative leap in pharmaceutical glass packaging, product upgrading, closely follow the trend of international high-quality pharmaceutical glass packaging, the company's business will be from the past Winning to win with high quality and high prices (the same specifications, the price of glass packs of Class I is several times the price of III glass packs), from the low end to the high end, the profit structure will be greatly changed.
The areas where the company may play a technical advantage in the future are:
Relying on the existing film bottle production technology, brown bottles (ie, brown molded bottles) can effectively reduce the weight and grade of grafted molded bottles, providing quality assurance for brown bottles to reach the international market. In the first half of 2006, the brown bottle gross margin was already Up to 44%, 6 percentage points higher than in 2005;
Butyl rubber has free substances, 3-6 months precipitation will affect the effect of drugs, production of butyl rubber stopper has a higher technical threshold, the company specializes in butyl rubber plug and liquid drug formulations compatibility experiments to hire domestic and foreign experts The research has achieved good progress and has become the only packaging enterprise in China that solves the compatibility problems of butyl rubber plugs and liquid drugs, and has made technical preparations for expanding the market share of high-grossing infusions for butyl rubber plugs in 2006 and 2007.
For high-end pharmaceuticals, the company has successfully developed coated rubber stoppers in China and is able to scale production. The cost is much lower than that of the Western-style company's siliconized coating and will be marketed in the future according to market demand;
The successful development of Type I glass has completely rewritten the market characteristics of the company in the past relying on scale and cost competition. In the future, it will shift to high value-added bio-agent pharmaceutical glass packaging and win with quality.
The company is the first pharmaceutical glass packaging company to install automatic inspection packaging machines in China. It is expected that the automatic inspection machine will replace manual inspections in 2007 and take a new step in the inspection technology of pharmaceutical glass packaging.
Entering the international market, it is gradually approaching the multinational giants
Molded bottles are the main packaging of injections, and the company has basically become a packaging supplier for multinational pharmaceutical companies in joint ventures and wholly-owned enterprises in China. With the growing maturity of the company's pharmaceutical glass packaging technology and the successful development of Class I glass, the company's market position has further improved in 2006, entered the international market, and gradually approaching the multinational giants:
The trend of transnational packaging giants is increasingly clear. The company is becoming an OEM manufacturer of multinational packaging companies. In 2006, OI and the company cooperated and had customized a brown bottle. In the future, the company will conduct deeper levels in the category I pharmaceutical glass bottles. Cooperation; Europe and the United States, the Middle East and other countries are continuously compressing the brown bottle packaging of oral liquid and immunomodulating oral preparations. The company will share the rapid increase in demand for brown bottles in the international market in the next few years. The brown bottle will become a new force for export products in 2006 and 2007. .
Formally becoming a global supplier of multinational pharmaceutical companies: The company is the fifth company in the world to produce Type I glass. The successful development of Type I glass enables the company to participate in the international market competition on glass materials, Shandong Medicine Glass Glass Pipe Pulling Technology and Germany. SCHOTT is approaching, the pharmaceutical packaging in the European market is taking a high-value route, and the gap in the new glass packaging market for molded bottles, controlled bottles, pre-filled syringes, cassette bottles, etc. produced by Type I pharmaceutical glass is large, and the company will soon participate in the international market. The market is competitive with new types of pharmaceutical glass packaging, and has participated in global bidding for pharmaceutical glass packaging of Pfizer Pharmaceuticals, and has officially become a global direct supplier of multinational pharmaceutical companies.
Type I glass molded bottles: mainly used for packaging plasma, albumin, globulin and other products, specifications in 20ml-100ml.
Type I glass control bottles: mainly used for packaging lyophilized biological agents, powder injections, vaccines, genetic engineering drugs and other products, specifications in 3ml-12ml, mainly 2ml-8ml, large specifications also have 32ml.
Clip-on bottle: foreign countries have partially replaced the injection Ampoule for packaging high-end large-capacity liquid dosage form drugs, domestic mainly for insulin injection packaging.
Pre-filled syringes: mainly used for packaging vaccines, interferon and other biological drugs, is a one-time drug-containing injections.
Brief introduction of two major glass packaging companies in Europe and America: There is no pure medical glass packaging company in the world
US OI: the world's largest glass packaging manufacturer, OI glass packaging involves food, beverages, cosmetics and pharmaceuticals, glass packaging revenue accounted for 89% of its business income, the other 11% is a plastic packaging, 2005 OI sales scale is 7079 Billion U.S. dollars, including glass packaging sales of 630 billion U.S. dollars.
Saint Gobain, France: The Saint Gobain business involves five areas. The packaging revenue only accounts for 11% of the company's business revenue. In 2005, the sales volume was 479.9 billion US dollars, and the glass packaging scale was even smaller. One of the company's five major businesses is Flat glass business.
Chinese medicine packaging has gone through three phases:
In the 50-60s: Brown bottles, straw cartons, and straight neck ampoule were the main packaging, and medicines were bulky and practical.
In the 60-80s, it was greatly influenced by the Cultural Revolution. From the end of the 1960s to the end of the 1970s, there was no registered trademark on pharmaceutical packaging. It was the painful period for pharmaceutical packaging in China and the development of pharmaceutical packaging was completely stagnant.
From the 1980s to the present: In the early 1980s, the registered trademark of drugs was restored, and the pharmaceutical packaging industry began to develop healthily. Composite materials such as aluminum-plastic, paper-plastic, and laser anti-counterfeit packaging materials were gradually popularized.
On April 29, 2004, China promulgated the "Measures for the Administration of Materials and Containers for Pharmaceutical Packaging (Provisional)", which classifies pharmaceutical packaging materials into three categories: I, II, and III:
Category I refers to materials and containers for pharmaceutical packaging that are directly in contact with drugs and used directly;
II refers to direct contact with drugs, but easy to clean, in the actual use of the process, after cleaning and can be disinfected and sterilized drug packaging materials, containers;
Category III refers to materials and containers for pharmaceutical packaging that may directly affect the quality of drugs other than Class I and II.
At present, the main pharmaceutical packaging materials mainly include the following major categories:
Rubber packing material: It mainly appears in the form of stoppers and gaskets for containers, which are divided into natural rubber and butyl rubber. Due to the poor sealability of natural rubber, it is necessary to seal the wax to supplement it, and the chemical properties are unstable. The government has been eliminated from the list. The butyl rubber has excellent sealing performance and replaces the natural rubber plug as an injection package.
Metal packaging materials: aluminum caps, pastes and aerosols used for powder injection packaging, and pharmaceutical aluminum foils for aluminum-plastic blister packaging. Aluminum-plastic composite covers have been accepted by more and more markets due to their easy opening and safe use. The aluminum-aluminum packaging developed in recent years is a new type of packaging material, which has a strong barrier property and can prolong the shelf life of drugs, and is particularly suitable for drugs with poor chemical stability.
Glass packaging material: It is widely used in the fields of injections, powder injections, biological medicines, blood products, lyophilizers, and oral liquids. Glass has good chemical stability, is not affected by the atmosphere, is not decomposed by solid or liquid substances of different chemical compositions, and the chemical properties and radiation resistance properties of the glass can be adjusted by changing the chemical composition of the glass, and the glass is transparent and beautiful. , low price, recyclable, etc., will not cause environmental problems.
Composite packaging materials: mainly including oral solid plastic bottles, liquid plastic bottles, etc., mostly made of high-density polyethylene or polypropylene, polyester materials.
2. China's largest pharmaceutical glass packaging company
Established in 1970, Shandong Pharmaceutical Glass Co., Ltd. started from antibiotic glass packaging, adopted low price to seize market share and continuously carried out technological innovation market strategy. The market share of molded antibiotic bottle reached 79%. It is the largest pharmaceutical glass packaging production enterprise in China.
At present, the company can produce six series of more than 400 kinds of products including molded antibiotic bottles, ampoules, control bottles, infusion bottles, glass tubes, and brown bottles, as well as butyl rubber stoppers, aluminum plastic caps, and plastic bottles, and have been successfully developed. Neutral borosilicate I glass has become the first domestic pharmaceutical glass packaging company capable of producing Class I glass in the world.
The company's total share capital is 222 million yuan, with unlimited sales of 155 million outstanding shares. The controlling shareholder of Wuyuan County Public Assets Management Committee holds 24.84% of the company's shares, unlimited-sale tradable shareholders hold 69.51% of the company's shares, and other limited-sale tradable shareholders hold 5.63% of the company's shares .
The company's main raw material soda ash accounts for about 10% of production costs, and the main energy-consuming coal accounts for about 18% of production costs. In 2004, the price of soda ash increased and the price of coal rose. Production costs rose by more than 30 million, and the government was originally scheduled for 2004. On December 31st, the butyl rubber stopper completely replaced the natural rubber stopper and the antibiotic stopper was delayed until June 30, 2005. The infusion stopper was postponed until December 31, 2005, which greatly affected the effectiveness of the raised funds. Even so, the company Still, through the technological innovation, the costs have risen and the profits have been steadily increasing.
3. Leading by size and cost, membrane resistance bottle is cash flow business
The antibiotic powder injection accounted for the absolute sales volume in the injection market in China. The company cultivated finely in the field of pharmaceutical glass packaging and formed a strong technical advantage. The market share of the membrane-resistant bottle reached 79%, and the production efficiency was higher than 70% of its counterparts. The interest rate is 10 points higher than that of competitors. Relying on technological innovation, the company's market competition strategy is to continuously reduce the price of common specification model anti-bottles, and to introduce high-gross-rate new products to replace old ones and gradually force competitors out of the market. It is expected that urban consumption in the antibiotic market will shrink in China, and rural consumption will increase steadily. The company is the main manufacturer of antibiotic molded bottles. The future size of membrane-resistant bottles is stable. The transfer to the Baotou industry may effectively reduce costs, and membrane resistance bottles become stable cash for the company. Streaming business.
Giants in antibiotic powder industry win customers with size and cost
The penicillin powder industry, which accounts for 70% of the antibiotic powder market share, shows high industrial concentration. 50-60% of production capacity is concentrated in four major manufacturers: Harbin Pharmaceuticals, Shijiazhuang Pharmaceuticals, North China Pharmaceuticals and Lukang Pharmaceuticals, including North China Pharmaceuticals. The annual production of penicillin powder is about 1.2 billion, which is mainly used in the packaging of controlled bottles. The remaining three companies use about 4 billion mold-resistant bottles each year. The company's mold-resistant bottles reach 8.7 billion, and it has the ability to cover downstream customers. We think the scale will become upstream. The bottleneck of competition in the packaging industry.
In recent years, the sales scale of the company’s top five sales customers has been stable at 1.8-1.9 billion yuan. Harbin Pharmaceuticals, Northeast Pharmaceuticals, Stone Drugs, Qilu, Shanghai Pioneer, and Shanghai New Asia, the heavyweight producers of antibiotic powder, are basically the company’s Drug companies are exploring the entry into the molded bottle industry. However, Shandong Pharmaceutical Glass Mould-resistance bottle prices are lower than drug companies entering the Mould-resistance bottle industry. They also make pharmaceutical companies continue to give up sales of more than 500 million yuan. Mold resistant bottle industry.
In addition, because pharmaceutical glass bottles account for a small proportion of drug value (1-10%), the first choice of glass bottles for downstream companies is to consider the stability of the quality of glass bottles in the process of continuous batch filling of large quantities of drugs and their suitability for filling equipment. The company has established a long-term and stable cooperative relationship with nearly 800 customers. The quality of the molded bottles produced has been fully adapted to the requirements of the downstream manufacturers on the mechanical strength and specifications of the bottles, which makes the company's customers have a good Continuity and stability.
Gross profit margin is 10 points higher than that of competitors, and profit is earned by technological superiority
In recent years, the company has continuously invested funds for technological transformation, and has independently developed domestic leading technologies such as lightweight thin-wall mold resistant bottle production technology, high white material mold anti-bottle production technology, servo parallel shear feeding technology, electric servo material feeding technology, and small-mouth pressure blowing technology. , For the transformation of purchased production equipment, not only the product quality has been improved, but also the production efficiency has been greatly improved. The production efficiency of one mold anti-bottle production line has been higher than 70% of the counterparts in 2003 and 2004, which makes the company model resistant to bottle hair. The interest rate is far higher than the average gross margin of the industry by more than ten points (the company's model bottle resistance rate was 41% in 2005, and the average gross margin of the industry was about 30%). The sales price of some products was close to the counterparty cost price, and the company completely relied on technological advantages to win. Take profits.
In 2004, when the cost increased by more than 30 million, the company improved its production efficiency through technological optimization. The company digested the cost of 25 million yuan, and the model-resistant bottle gross margin remained high, reflecting the company’s strong internal management, technical capabilities, and competitiveness.
Adjust product structure and stabilize the leading position in the industry
At present, the company's mold resistance bottle specifications from the 5ml-100ml nearly 300 species, while the peer company can only produce a maximum of 10 specifications. Through the continuous introduction of high-gross new product replacements, lowering the price of competitors' existing model-resistant bottles, cracking down on competitors and gradually forcing competitors out of the market, the company’s market strategy has achieved absolute results, and the industry’s leading position has been steadily consolidated.
In response to the trend of modularization and anti-bottles, the company took advantage of 30 years of accumulated experience in the glass packaging industry to continuously research and develop new-type die-resistant bottles. It is the first lightweight, high-grade, and large-format one in the industry, leading the industry in consumer trends, and Saint Gobain in France fights for Pfizer's high-end customers.
Membrane resistance bottle transfer to Baotou industry will effectively reduce costs and become a cash flow business
As China's unique prescription drug clinical marketing model, urban hospital sales of oral antibiotics swollen, antibiotic powder is mainly on the amount of "virtual praise", sales of water is not great, but with the rational rationality of medication, the future of China's urban hospital antibiotics The consumption of injections has shrunk, and rural areas have become the main force for the increase in the consumption of antibiotics. The company is the main manufacturer of membrane-resistant bottles, and the scale of membrane-resistant bottles is stable in the future.
Membrane resistance bottles are being transferred to the Baotou industry. Due to the availability of local coal and soda ash and tax concessions of 15%, Baotou’s subsidiary Kangyu’s strategic positioning is a company’s Class III glass mold resistant bottle production base. The local coal price is only RMB 200/ton. (Company headquarters 506 yuan / ton), electricity price 0.40 yuan / degree (Corporate headquarters 0.57 yuan / degree), we expect membrane resistance to the entire bottle after the transfer, the long-term gross margin may rise to 45-46%, membrane resistance bottle future contributions to the company The net profit will stabilize at 80 million to 110 million yuan, becoming the company's cash flow business.
4. Take the road of technological innovation, and gradually approach the multinational giants
Before 2003, all technologies of the company centered on the glass industry, and had strong technological advantages in glass packaging. In the pharmaceutical industry, it was only a registered barrier for pharmaceutical packaging controlled by the government. After the intervention in the production of butyl rubber plugs in 2003, the company used pharmaceuticals. Glass packaging began to be fully integrated with drugs. Medicinal glass packaging is not a simple glass bottle, but a medicinal glass that can guarantee the safety of injected drugs. Drug packaging must also be compatible with drugs while packaging drugs. Sex will not react with drugs, causing greater drug safety problems.
Continuous technological innovation in the field of pharmaceutical packaging, product upgrading in 2007
The company's membrane resistant bottles continued to undergo technological transformation and the technical potential was basically brought into play. In 2003, the "bottle + lid" strategy was involved in butyl rubber stoppers. The company's glass packaging began to merge with the pharmaceutical industry. In 2004, the company developed I-type glass for two years. Difficulties, breakthrough in technology in 2006; success in 2007 relying on type I glass, the company will undergo a qualitative leap in pharmaceutical glass packaging, product upgrading, closely follow the trend of international high-quality pharmaceutical glass packaging, the company's business will be from the past Winning to win with high quality and high prices (the same specifications, the price of glass packs of Class I is several times the price of III glass packs), from the low end to the high end, the profit structure will be greatly changed.
The areas where the company may play a technical advantage in the future are:
Relying on the existing film bottle production technology, brown bottles (ie, brown molded bottles) can effectively reduce the weight and grade of grafted molded bottles, providing quality assurance for brown bottles to reach the international market. In the first half of 2006, the brown bottle gross margin was already Up to 44%, 6 percentage points higher than in 2005;
Butyl rubber has free substances, 3-6 months precipitation will affect the effect of drugs, production of butyl rubber stopper has a higher technical threshold, the company specializes in butyl rubber plug and liquid drug formulations compatibility experiments to hire domestic and foreign experts The research has achieved good progress and has become the only packaging enterprise in China that solves the compatibility problems of butyl rubber plugs and liquid drugs, and has made technical preparations for expanding the market share of high-grossing infusions for butyl rubber plugs in 2006 and 2007.
For high-end pharmaceuticals, the company has successfully developed coated rubber stoppers in China and is able to scale production. The cost is much lower than that of the Western-style company's siliconized coating and will be marketed in the future according to market demand;
The successful development of Type I glass has completely rewritten the market characteristics of the company in the past relying on scale and cost competition. In the future, it will shift to high value-added bio-agent pharmaceutical glass packaging and win with quality.
The company is the first pharmaceutical glass packaging company to install automatic inspection packaging machines in China. It is expected that the automatic inspection machine will replace manual inspections in 2007 and take a new step in the inspection technology of pharmaceutical glass packaging.
Entering the international market, it is gradually approaching the multinational giants
Molded bottles are the main packaging of injections, and the company has basically become a packaging supplier for multinational pharmaceutical companies in joint ventures and wholly-owned enterprises in China. With the growing maturity of the company's pharmaceutical glass packaging technology and the successful development of Class I glass, the company's market position has further improved in 2006, entered the international market, and gradually approaching the multinational giants:
The trend of transnational packaging giants is increasingly clear. The company is becoming an OEM manufacturer of multinational packaging companies. In 2006, OI and the company cooperated and had customized a brown bottle. In the future, the company will conduct deeper levels in the category I pharmaceutical glass bottles. Cooperation; Europe and the United States, the Middle East and other countries are continuously compressing the brown bottle packaging of oral liquid and immunomodulating oral preparations. The company will share the rapid increase in demand for brown bottles in the international market in the next few years. The brown bottle will become a new force for export products in 2006 and 2007. .
Formally becoming a global supplier of multinational pharmaceutical companies: The company is the fifth company in the world to produce Type I glass. The successful development of Type I glass enables the company to participate in the international market competition on glass materials, Shandong Medicine Glass Glass Pipe Pulling Technology and Germany. SCHOTT is approaching, the pharmaceutical packaging in the European market is taking a high-value route, and the gap in the new glass packaging market for molded bottles, controlled bottles, pre-filled syringes, cassette bottles, etc. produced by Type I pharmaceutical glass is large, and the company will soon participate in the international market. The market is competitive with new types of pharmaceutical glass packaging, and has participated in global bidding for pharmaceutical glass packaging of Pfizer Pharmaceuticals, and has officially become a global direct supplier of multinational pharmaceutical companies.
Wig accessories range is full of all those little necessities that keep your wig looking fabulous for longer.
Accessories products include Wig combs, Wig Clips, sewing needles, T-pins and hair drawing mat etc, all working behind the scenes to give you a beautiful head of hair.
Wig making tools are great for making sure your wig stays secure all day. Our Wig accessories collection comes in a wide range of colours size, so your wig, hairpiece or hair extensions will blend in perfectly.
We have a fabulous range of Wig Accessories at affordable prices. You`ll find the wig accessories you need to keep your wig looking great as well as styled in your unique way.
Wig Accessories,Wig Clips, Hair Holder Drawing Mat,T Pins Needles,Sewing C Shape Needles
Xuchang Le Yi De Import And Export Trade Co., Ltd. , https://www.lileaderbeauty.com